Effect of human milk oligosaccharide on the liver-skeletal muscle axis in streptozotocin-induced metabolic stress
- 1College of Pharmacy, Chungnam National University Daejeon 34134 Korea
Abstract
Type 1 diabetes mellitus is characterized by insulin deficiency, hyperglycemia, and systemic metabolic and inflammatory disturbances that lead to multi-organ injury. Building on prior evidence that 6'-sialyllactose (SL), a sialylated human milk oligosaccharide, exerts anti-inflammatory and metabolic benefits, we investigated whether SL mitigates streptozotocin (STZ)-induced metabolic dysfunction and tissue injury in vivo. Male ICR mice were pretreated with SL (25 or 75 mg/kg) prior to STZ administration. STZ challenge markedly increased serum glucose levels, disrupted hepatic enzyme profiles, impaired protein metabolism, and induced liver apoptosis and inflammation. SL pretreatment significantly improved glucose homeostasis, normalized liver enzyme activities and serum protein indices, reduced hepatic caspase-3 activation, and suppressed pro-inflammatory cytokine expression in the liver and skeletal muscle. Mechanistically, SL restored AMPK-Akt-mTOR signaling in metabolic tissues. Collectively, these data demonstrate that SL confers systemic metabolic protection against STZ-induced diabetes, highlighting its potential as a therapeutic or preventive agent targeting inflammatory and metabolic pathways.
Related
- Empagliflozin does not rescue nor exacerbate doxorubicin-induced skeletal muscle wasting and metabolic dysfunction in male mice
- Stable isotope‐derived measurements of protein synthesis detect amino acid‐induced anabolism in skeletal muscle microtissues not captured by puromycin labelling
- Total Phenylethanoid Glycosides from Cistanche tubulosa Alleviate 5-Fluorouracil-Induced Fatigue-Like Behavior and Skeletal Muscle Injury in Mice
- A complementary amino acid formulation enhances exercise-induced skeletal muscle remodeling during resistance training
- Skeletal Muscle PGC-1α1 Modulates Kynurenine Metabolism and Mediates Resilience to Stress-Induced Depression
BibTeX
@article{phan2026effect,
title = {{Effect of human milk oligosaccharide on the liver-skeletal muscle axis in streptozotocin-induced metabolic stress}},
author = {Lan Phuong Phan and Thuy Le Lam Nguyen and Phuc Nguyen Tran-Duc and Kyung-Sun Heo},
journal = {The Korean Journal of Physiology \& Pharmacology : Official Journal of the Korean Physiological Society and the Korean Society of Pharmacology},
year = {2026},
month = nov,
doi = {10.4196/kjpp.26.014},
url = {https://doi.org/10.4196/kjpp.26.014},
note = {CC BY-NC 4.0},
}
RIS
TY - JOUR
TI - Effect of human milk oligosaccharide on the liver-skeletal muscle axis in streptozotocin-induced metabolic stress
AU - Lan Phuong Phan
AU - Thuy Le Lam Nguyen
AU - Phuc Nguyen Tran-Duc
AU - Kyung-Sun Heo
PY - 2026
DA - 2026/11/01
JO - The Korean Journal of Physiology & Pharmacology : Official Journal of the Korean Physiological Society and the Korean Society of Pharmacology
DO - 10.4196/kjpp.26.014
UR - https://doi.org/10.4196/kjpp.26.014
AB - Type 1 diabetes mellitus is characterized by insulin deficiency, hyperglycemia, and systemic metabolic and inflammatory disturbances that lead to multi-organ injury. Building on prior evidence that 6'-sialyllactose (SL), a sialylated human milk oligosaccharide, exerts anti-inflammatory and metabolic benefits, we investigated whether SL mitigates streptozotocin (STZ)-induced metabolic dysfunction and tissue injury in vivo. Male ICR mice were pretreated with SL (25 or 75 mg/kg) prior to STZ administration. STZ challenge markedly increased serum glucose levels, disrupted hepatic enzyme profiles, impaired protein metabolism, and induced liver apoptosis and inflammation. SL pretreatment significantly improved glucose homeostasis, normalized liver enzyme activities and serum protein indices, reduced hepatic caspase-3 activation, and suppressed pro-inflammatory cytokine expression in the liver and skeletal muscle. Mechanistically, SL restored AMPK-Akt-mTOR signaling in metabolic tissues. Collectively, these data demonstrate that SL confers systemic metabolic protection against STZ-induced diabetes, highlighting its potential as a therapeutic or preventive agent targeting inflammatory and metabolic pathways.
SN - 1226-4512
SN - 2093-3827
ER -